These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22231078)

  • 21. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 22. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 23. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 24. 25 top health care stocks. Will they lead the next market boom?
    Kane L
    Med Econ; 2001 Apr; 78(7):126-8, 133-6, 140-2. PubMed ID: 11368040
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotechs hedge against big pharma givebacks.
    Dorey E
    Nat Biotechnol; 1999 May; 17(5):416-7. PubMed ID: 10331784
    [No Abstract]   [Full Text] [Related]  

  • 26. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
    Pallarito K
    Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390
    [No Abstract]   [Full Text] [Related]  

  • 27. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 28. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 29. 2Q10-spreading the wealth.
    Yang W
    Nat Biotechnol; 2010 Aug; 28(8):771. PubMed ID: 20697393
    [No Abstract]   [Full Text] [Related]  

  • 30. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The other side of being CFO.
    Benner K
    Fortune; 2012 Oct; 166(6):58. PubMed ID: 23072075
    [No Abstract]   [Full Text] [Related]  

  • 32. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 33. The money men.
    Alper J
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE7-12. PubMed ID: 12874970
    [No Abstract]   [Full Text] [Related]  

  • 34. Gates eyes biotechs as for-profit investments.
    Orelli B
    Nat Biotechnol; 2011 Jul; 29(7):559. PubMed ID: 21747367
    [No Abstract]   [Full Text] [Related]  

  • 35. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 37. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech venture capital--it's not too late to be early.
    Klausner A
    Nat Biotechnol; 2005 Apr; 23(4):417-8. PubMed ID: 15815662
    [No Abstract]   [Full Text] [Related]  

  • 39. Nasdaq restructures biotech index.
    Morrison C
    Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
    [No Abstract]   [Full Text] [Related]  

  • 40. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.